Company news
Instil Bio, Inc. (NASDAQ:TIL) news
Instil Bio, Inc. news releases on 6ix. Latest, Aug 13, 2026: Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Press releases & updates
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026
Instil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 26, 2026
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
January 6, 2026
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 13, 2025
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed, Refractory Solid Tumors
July 3, 2025
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 2, 2025
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
June 2, 2025
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 30, 2025
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
May 22, 2025
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 4, 2025
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
January 13, 2025
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
September 15, 2024
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
July 31, 2024
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 9, 2024
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 20, 2024
Instil Bio Announces Strategic Update
January 15, 2024
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 4, 2023
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 12, 2023
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 5, 2023
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 13, 2023
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 25, 2023
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
January 30, 2023
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
January 8, 2023
Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce
December 7, 2022
Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 13, 2022
Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 7, 2022
Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing
October 30, 2022
Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer
October 17, 2022
Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer
September 5, 2022
Instil Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022
Instil Bio Announces IND Clearance of First CoStAR-TIL program, ITIL-306, Designed to Enhance Activity in the Tumor Microenvironment
May 26, 2022
Instil Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 15, 2022
Instil Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 6, 2022
Instil Bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 14, 2021
Instil Bio Announces Poster Presentations at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 14, 2021
Instil Bio Presents Subset Analysis of Patients with Checkpoint-Refractory Advanced Melanoma from Compassionate Use Study at 2021 ESMO Congress
September 15, 2021
Instil Bio Receives IND Clearance to Initiate a Phase 2 Clinical Trial for Patients with Advanced Melanoma
September 12, 2021
Instil Bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 11, 2021
Instil Bio Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 12, 2021
Instil Bio Receives Orphan Drug Designation for ITIL-168 in Melanoma
April 26, 2021